CYTK
$65.91+0.41%
as of close, Sep 30, 2026
☾ AH $65.91 +0.41%
Cytokinetics IncorporatedStock · Health CareRussell 2000 0.3%Nasdaq Composite 0.02%US Stock Market 0.02%Russell 3000 0.02%
CYTK financial statements
The full income statement, balance sheet, and cash-flow statement for Cytokinetics Incorporated (CYTK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 109.2M2024-09 118.0M2024-12 118.4M2025-03 119.4M2025-06 119.7M2025-09 122.3M2025-12 123.2M2026-03 124.4M2026-06 132.1M+20.9% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 88.0M+376.6% | 18.5M+145.3% | 7.53M-92.0% | 94.6M+34.3% | 70.4M+26.2% | |
| 700M+26.2% | 555M+10.1% | 504M+20.3% | 419M+63.1% | 257M+71.4% | ||
| Research & development | 416M+22.6% | 339M+2.8% | 330M+37.1% | 241M+50.6% | 160M+65.0% | |
| Selling, general & administrative | 284M+32.0% | 215M+24.0% | 174M-2.5% | 178M+83.9% | 96.8M+83.3% | |
| General & administrative | 284M+32.0% | 215M+24.0% | 174M-2.5% | 178M+83.9% | 96.8M+83.3% | |
| Operating income | -612M-14.2% | -536M-8.1% | -496M-53.1% | -324M-74.0% | -186M-98.3% | |
| Interest expense | 45.6M+20.9% | 37.7M+33.2% | 28.3M+45.8% | 19.4M+18.1% | 16.4M+3.0% | |
| Interest & investment income | — | — | — | 11.4M+1040.0% | 1.00M-81.1% | |
| Other non-operating income | 48.4M-6.0% | 51.5M+86.5% | 27.6M+143.6% | 11.3M+3326.6% | 331K-93.8% | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -785M-33.2% | -590M-12.0% | -526M-35.3% | -389M-80.6% | -215M-69.2% | |
| -$6.54-24.3% | -$5.26+3.5% | -$5.45-25.9% | -$4.33-54.6% | -$2.80-42.1% | ||
| EPS (basic) | -$6.54-24.3% | -$5.26+3.5% | -$5.45-25.9% | -$4.33-54.6% | -$2.80-42.1% | |
| Weighted-avg shares (basic) | 120M+7.3% | 112M | — | — | — | |
| Weighted-avg shares (diluted) | 120M+7.3% | 112M | — | — | — | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 917M-17.2% | 1.11B+76.4% | 628M-21.0% | 795M+48.4% | 536M+13.0% | ||
| Cash & equivalents | 123M+29.2% | 94.9M-16.1% | 113M+72.3% | 65.6M-41.8% | 113M+35.8% | |
| Cash & short-term investments | 1.20B+0.0% | 1.20B+83.1% | 655M-21.0% | 829M+33.0% | 624M+24.5% | |
| Accounts receivable | 17.8M+6.7% | 16.6M+1197.7% | 1.28M+772.8% | 147K-99.7% | 51.8M+1072.4% | |
| Inventory | 0.00 | — | — | — | — | |
| Prepaid expenses | 17.0M+11.2% | 15.3M+27.9% | 11.9M-4.2% | 12.5M+2.0% | 12.2M+112.8% | |
| 1.42B+1.6% | 1.40B+70.0% | 824M-18.8% | 1.01B+20.6% | 841M+57.6% | ||
| Property, plant & equipment | 79.2M+20.3% | 65.8M-4.3% | 68.7M-14.5% | 80.5M+9.8% | 73.3M+449.0% | |
| Operating lease right-of-use | 76.0M+1.1% | 75.2M-4.8% | 79.0M-4.5% | 82.7M+13.1% | 73.1M+2401.3% | |
| Other non-current assets | 17.3M+125.1% | 7.71M-3.6% | 8.00M-17.5% | 9.69M+34.8% | 7.19M+13.1% | |
| 202M+12.7% | 180M+75.0% | 103M+21.3% | 84.6M+17.8% | 71.9M+130.3% | ||
| Accounts payable | 22.3M+9.7% | 20.4M-5.3% | 21.5M-16.0% | 25.6M+21.5% | 21.1M+162.0% | |
| Accrued liabilities | 83.3M+50.5% | 55.3M+29.7% | 42.6M-3.3% | 44.1M+28.3% | 34.4M+77.9% | |
| Deferred revenue | 1.61M-96.9% | 52.4M | 0.00 | — | — | |
| Short-term & current debt | 41.2M+257.5% | 11.5M+14.3% | 10.1M+952.2% | 958K | — | |
| Current lease liability | 19.1M+0.7% | 19.0M+6.1% | 17.9M+39.5% | 12.8M-13.7% | 14.9M+433.7% | |
| Other current liabilities | 3.83M-60.9% | 9.81M-7.1% | 10.6M+840.2% | 1.12M-27.1% | 1.54M+46.8% | |
| 2.08B+35.6% | 1.54B+27.0% | 1.21B+7.8% | 1.12B+87.9% | 597M+42.1% | ||
| Long-term debt | 246M+164.3% | 93.2M+59.7% | 58.4M-8.5% | 63.8M+34.7% | 47.4M+2.5% | |
| Deferred revenue (non-current) | — | — | — | 0.00-100.0% | 87.0M+0.0% | |
| Non-current lease liability | 108M-4.1% | 113M-6.5% | 120M-5.1% | 127M+13.1% | 112M+25406.6% | |
| Operating lease liability (total) | 127M-3.4% | 132M-4.9% | 138M-1.0% | 140M+9.9% | 127M+3840.8% | |
| Finance lease liability (total) | — | 204K-82.2% | 1.14M-42.9% | 2.00M+53.3% | 1.30M | |
| Other non-current liabilities | — | 0.00-100.0% | 186K-82.2% | 1.04M-76.6% | 4.46M | |
| -660M-387.3% | -135M+65.0% | -386M-258.0% | -108M-144.2% | 244M+115.1% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 123K+4.2% | 118K+15.7% | 102K+8.5% | 94.0K+11.9% | 84.0K+20.0% | |
| Additional paid-in capital | 2.83B+10.2% | 2.56B+48.6% | 1.73B+16.5% | 1.48B+2.0% | 1.45B+31.4% | |
| Retained earnings | -3.49B-29.1% | -2.70B-27.9% | -2.11B-33.2% | -1.59B-31.3% | -1.21B-21.7% | |
| Accumulated other comprehensive income | 630K-73.7% | 2.40M+24080.0% | -10.0K+99.7% | -3.59M-313.1% | -869K-683.2% | |
| Total liabilities & equity | 1.42B+1.6% | 1.40B+70.0% | 824M-18.8% | 1.01B+20.6% | 841M+57.6% | |
| Common shares issued | 123M+4.0% | 118M+16.3% | 102M+7.2% | 94.8M+11.8% | 84.8M+19.4% | |
| Common shares outstanding | 123M+4.0% | 118M+16.3% | 102M+7.2% | 94.8M+11.8% | 84.8M+19.4% | |
| Shares outstanding (cover) | 123M+4.0% | 118M+15.0% | 103M+8.2% | 95.2M+12.1% | 84.9M+19.3% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -510M-28.8% | -396M+4.5% | -414M-38.3% | -300M-110.2% | -143M-1693.7% | ||
| Depreciation & amortization | 10.1M+6.2% | 9.53M-19.9% | 11.9M+104.5% | 5.81M+155.4% | 2.28M+24.3% | |
| Share-based compensation | 112M+14.8% | 97.8M+35.8% | 72.1M+50.6% | 47.9M+78.3% | 26.8M+52.3% | |
| Change in receivables | 1.11M-92.8% | 15.4M+1252.7% | 1.14M+102.0% | -56.7M-219.6% | 47.4M+6479.4% | |
| 16.7M+103.0% | -553M-331.2% | 239M+191.3% | -262M-77.4% | -148M+24.8% | ||
| Capital expenditure | 24.8M+535.1% | 3.91M+175.8% | 1.42M-87.5% | 11.3M-76.8% | 48.9M+342.2% | |
| Free cash flow | -535M-33.8% | -400M+3.8% | -416M-33.7% | -311M-62.4% | -191M-8975.1% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales/maturities of investments | 1.10B+48.3% | 744M-14.5% | 871M+44.0% | 605M+43.0% | 423M+71.0% | |
| 524M-43.6% | 931M+320.5% | 221M-57.1% | 516M+61.3% | 320M+36.7% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 10.8M+24.5% | 8.68M | 0.00-100.0% | 47.7M | 0.00 | |
| Common stock issued | 0.00 | 0.00-100.0% | 164M | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | -715K-442.1% | 209K+1145.0% | -20.0K | — | — | |
| Net change in cash | 30.4M+267.3% | -18.2M-139.3% | 46.2M+201.6% | -45.5M-253.2% | 29.7M-36.2% | |
| Interest paid | 22.9M-11.8% | 26.0M+152.3% | 10.3M-32.1% | 15.2M+65.3% | 9.18M-4.6% | |
| Income taxes paid | 0.00 | 0.00 | 0.00 | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 7.83B+40.5% | 5.57B-32.0% | 8.19B+88.8% | 4.34B+12.1% | 3.87B+161.7% | |
| P/S | 88.9×-70.5% | 301.5×-71.2% | 1047.5×+3481.1% | 29.3×-46.7% | 54.9×+107.5% | |
| P/B | — | — | — | — | 15.9×+21.7% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: CYTK’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CYTK filings on SEC EDGAR → Not investment advice.